HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

TPI ASM8

a mixture of two modified phosphorothioate antisense oligonucleotides; an anti-asthmatic agent

Also Known As:

ASM8 oligonucleotide

Networked: 4 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Nucleic Acids, Nucleotides, and Nucleosides: 1
- Nucleotides: 15763
  - Polynucleotides: 218
    - Oligonucleotides: 5145
      - Phosphorothioate Oligonucleotides: 65
        TPI ASM8: 4

Experts

1.	Campbell, H: 2 articles (12/2011 - 09/2011)
2.	Gauvreau, G M: 2 articles (12/2011 - 09/2011)
3.	Mistry, M: 2 articles (12/2011 - 09/2011)
4.	Renzi, Paolo M: 2 articles (12/2008 - 05/2008)
5.	Babirad, I: 1 article (12/2011)
6.	Imaoka, H: 1 article (12/2011)
7.	Sehmi, R: 1 article (12/2011)
8.	Watson, R M: 1 article (12/2011)
9.	Carballo, D: 1 article (09/2011)
10.	D'Anjou, H: 1 article (09/2011)

Related Diseases

1.	Asthma (Bronchial Asthma) 05/01/2008 - "Seventeen subjects with mild atopic asthma were randomized in a crossover study to inhale 1,500 microg TPI ASM8 or placebo by nebulizer, once daily for 4 days. " 12/01/2008 - "TPI ASM8 and TPI 1100 are two products containing modified phosphorothioate antisense oligonucleotides (AONs), which are undergoing development for the treatment of asthma and chronic obstructive pulmonary disease (COPD), respectively. " 09/01/2011 - "TPI ASM8 attenuated a broad range of inflammatory and physiological changes after AIC, suggesting that CCR3, IL-3, and GM-CSF also are important targets for the management of asthma." 05/01/2008 - "TPI ASM8 attenuates the allergen-induced increase in target gene mRNA and airway responses in subjects with mild asthma. "
2.	Chronic Obstructive Pulmonary Disease (COPD) 12/01/2008 - "TPI ASM8 and TPI 1100 are two products containing modified phosphorothioate antisense oligonucleotides (AONs), which are undergoing development for the treatment of asthma and chronic obstructive pulmonary disease (COPD), respectively. "
3.	Inflammation (Inflammations) 05/01/2008 - "The drug product TPI ASM8 contains two modified phosphorothioate antisense oligonucleotides designed to inhibit allergic inflammation by down-regulating human CCR3 and the common beta chain (beta(c)) of IL-3, IL-5, and granulocyte-macrophage colony-stimulating factor receptors. "
4.	Eosinophilia 12/01/2011 - "Inhalation of TPI ASM8 significantly improves lung function and sputum eosinophilia after allergen inhalation challenge in asthmatics. "

Related Drugs and Biologics

1.	Antisense Oligonucleotides
2.	Interleukin-3 (Interleukin 3)
3.	Allergens
4.	Granulocyte-Macrophage Colony-Stimulating Factor Receptors (GM-CSF Receptor)
5.	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
6.	Interleukin-5 (Interleukin 5)
7.	Messenger RNA (mRNA)

Related Therapies and Procedures

1.	Nebulizers and Vaporizers (Inhaler)